When Zamann Pharma Support was hired to implement a robust Computerized Systems Validation (CSV) SOP in a German pharmaceutical manufacturer, we expected the usual challenges: legacy systems, documentation gaps, and scattered validation status.
But what we found was much bigger.
The real bottleneck was not the CSV process.
It was the lack of a strong Quality Management System (QMS) behind it. And this is precisely why most CSV initiatives collapse before they even begin.
1. The Hidden Truth: CSV Does Not Live in Isolation
Many companies approach CSV as a “technical task” — a protocol to write, a validation to perform, a checklist to submit.
But CSV is only as strong as the Quality System that governs it.
Without a properly defined Quality structure, approval chain, training process, deviation handling, change control, and ownership… even the best CSV strategy becomes operationally weak and regulatory-vulnerable.
Zamann’s assessment at the German site revealed critical gaps:
- No clear hierarchy within Quality functions; decisions were slowed or blocked.
- The QA department was not responsible for activities that should legally belong to QA.
- SOPs that directly impact CSV (Change Control, Risk Management, Deviation Management, Audit Trail Review, Periodic Review, Data Integrity…) were superficial or outdated.
- IT was operating independently from Quality — and often made decisions affecting GxP systems without QA review.
- Protocol approval often depended on non-GMP departments.
The result?
Validation efforts were greatly delayed, documentation was inconsistent, and no inspector would accept such a framework.
2. Quick Self-Diagnostic — Does This Apply to Your Company?
- CSV activities depend on individuals, not on defined processes
- Your change control SOP is generic and not adapted to computerized systems
- QA approves documents but does not lead or own the validation process
- Roles & responsibilities for CSV are not clearly defined
- IT implements GxP-relevant changes without QA oversight
- There is no validated training system to ensure qualification of key staff
- CSV protocols take months to be approved
- No periodic review of validated systems
- Audit Trail Reviews are rarely performed
- SOPs are written only to pass inspections — not to guide operations
If you checked more than 3 items — your CSV is already at risk.
3. Real Case: The German Manufacturer
Real case: The German Manufacturer
When Zamann began its intervention, the initial request was simple: “Help us develop a strong SOP for CSV.”
But after analysis, we had to say something uncomfortable: “A CSV SOP alone will not solve your problem. You need to fix your QMS first.”
Main Findings
-
QA Organizational Structure
Undefined hierarchy & unclear roles
No accountability for CSV -
Change Control
Generic, not IT/CSV adapted
Uncontrolled technical changes -
Training
No validated training tracking
Validation performed by unqualified staff -
SOP Network
Incomplete/not integrated
Inconsistent validation documentation -
Ownership
IT often led CSV decisions
Lack of GxP governance -
Periodic Review
Not implemented
CSV becomes obsolete over time
Conclusion:
CSV was not the problem — QMS maturity was.
4. Why a Weak QMS Damages CSV — Cause & Effect
Poor Role Definition → Slow Decision Making. When QA leadership is unclear, document approval becomes painful. CSV projects stagnate.
SOPs Not Interconnected → CSV Operates in a Vacuum. If Deviation Management, Risk Management, and Change Control do not support CSV, daily operations become inconsistent and non-compliant.
No Governance on IT Activities → Silent Non-Compliance. IT makes changes that directly affect validated systems — but without QA supervision, this is a direct violation of FDA and EMA expectations.
No Periodic Review → Validation Expires. CSV is not a “one-time project.” A QMS must guarantee continued state of control. Without it, inspectors assume loss of validated status.
5. Compliance Clarity — What Regulators Expect
- FDA 21 CFR Part 820.70(i) Requires validated systems and controlled processes
- EU GMP Annex 11 CSV must be governed by quality risk management
- EU GMP Part I, Chapter 1 QMS must ensure state of control over computerized systems
- PIC/S PI-011 QA must oversee and approve all validation activities
- FDA CSA (2022) Assurance demands integration of CSV with overall QMS
Inspectors do not check only CSV documentation — they verify its integration into the Quality System.
6. What To Do Next — Action Plan
-
Step 1 — Perform a QMS Maturity Assessment
Map all SOPs, roles, and responsibilities. Identify missing links between them. -
Step 2 — Define Ownership of CSV
Formalize responsibilities: QA must lead; IT & Business are support functions. -
Step 3 — Strengthen the SOP Network
Create interdependencies: Change Control must trigger CSV assessment; Deviation Management must include CSV evaluation; Periodic Review must assess validation status; Risk Assessment must follow GAMP5 guidance. -
Step 4 — Train & Qualify Personnel
Training records must prove that staff is qualified before performing validation tasks. -
Step 5 — Build Governance
Define a clear approval workflow & escalation process. No ambiguity. -
Step 6 — Implement Periodic Review
Validation is not a milestone — it is a maintenance activity.
7. Leadership Insight — Compliance Is Strategy
A weak QMS does not only create regulatory risk.
It slows decisions. It increases costs. It leads to fragmented responsibilities. It destroys credibility.
In the future pharma industry, Quality is not a department — it will be an operational core.
The companies that understand this will not only pass inspections, they will lead the market. And those with weak QMS foundations will keep spending money on patches that never solve the root problem.
